Skip to main content
Top

03-02-2025 | Original Research Article

Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital

Authors: Franck Neil El Sissy, Annouk Bisdorff, Alexandre Perrier, Erell Guillerm, Jérôme Denis, Löetitia Favre, Mathilde Aubertin, Mélanie Eyries, Florence Coulet

Published in: Molecular Diagnosis & Therapy

Login to get access

Abstract

Background and Objective

Superficial vascular anomalies are complex disorders characterized by abnormal vascular growth. Next-generation sequencing has recently identified somatic genetic alterations associated with these malformations, offering new insights for targeted treatments. However, tissue biopsies for genetic testing can be invasive and difficult to obtain, especially in arteriovenous malformations (AVM) with hemorrhagic risks. A liquid biopsy, a non-invasive approach, offers a promising solution by detecting genetic mutations in cell-free DNA. This pilot study aimed to evaluate the feasibility of using a liquid biopsy for the genetic analysis of patients with superficial vascular anomalies through cell-free DNA sampling. Additionally, it explored whether specific sampling sites, such as the afferent artery, nidus, and efferent vein, could enhance the sensitivity of detecting pathogenic variants in patients with AVM.

Methods

A total of 88 patients were enrolled, including 55 with AVM and 33 with lymphatic malformations. For patients with AVM, cell-free DNA samples were collected from peripheral blood, efferent veins, afferent arteries, and the AVM nidus. In patients with lymphatic malformations, cystic lymphatic fluid was collected by a direct puncture during diagnostic procedures. A molecular analysis was performed using a targeted gene panel relevant to somatic alterations in solid tumors. Pathogenic variants were validated by digital polymerase chain reaction for patients with lymphatic malformations.

Results

Pathogenic variants were identified in 23.6% of patients with AVM, predominantly in MAP2K1 and KRAS genes, with higher sensitivity near the AVM nidus. In addition, pathogenic variants were identified in 27.3% of patients with lymphatic malformations, all involving the PIK3CA gene. Despite the lower sensitivity of a cell-free DNA analysis compared with a tissue biopsy, especially in patients with AVM, the detection rate suggests the utility for a cell-free DNA analysis, particularly when a tissue biopsy is not feasible.

Conclusions

This study confirms the feasibility of using a cell-free DNA liquid biopsy for genotyping patients with superficial vascular anomalies, although a tissue biopsy remains the gold standard for comprehensive genetic profiling because of its higher sensitivity. A liquid biopsy offers a non-invasive option for molecular analysis that is useful as a preliminary or alternative approach when direct tissue sampling is not possible. Importantly, the sensitivity of cell-free DNA sampling in AVM appeared highest when obtained close to the nidus, indicating an optimal sampling location for future studies. Further research is needed to improve detection sensitivity, especially for samples taken near the nidus, to validate and strengthen these findings. Although our study focused on superficial/extra-cranial AVM, further research should assess the applicability of this approach to cerebral AVM, where a tissue biopsy is particularly risky.
Literature
1.
go back to reference Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136:e203–14.PubMedCrossRef Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136:e203–14.PubMedCrossRef
2.
go back to reference Nguyen H-L, Boon LM, Vikkula M. Genetics of vascular anomalies. Semin Pediatr Surg. 2020;29: 150967.PubMedCrossRef Nguyen H-L, Boon LM, Vikkula M. Genetics of vascular anomalies. Semin Pediatr Surg. 2020;29: 150967.PubMedCrossRef
3.
go back to reference Couto JA, Ayturk UM, Konczyk DJ, Goss JA, Huang AY, Hann S, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis. 2017;20:303–6.PubMedPubMedCentralCrossRef Couto JA, Ayturk UM, Konczyk DJ, Goss JA, Huang AY, Hann S, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis. 2017;20:303–6.PubMedPubMedCentralCrossRef
4.
go back to reference El Sissy FN, Wassef M, Faucon B, Salvan D, Nadaud S, Coulet F, et al. Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations. J Eur Acad Dermatol Venereol. 2022;36:905–12.PubMedCrossRef El Sissy FN, Wassef M, Faucon B, Salvan D, Nadaud S, Coulet F, et al. Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations. J Eur Acad Dermatol Venereol. 2022;36:905–12.PubMedCrossRef
5.
go back to reference Couto JA, Huang AY, Konczyk DJ, Goss JA, Fishman SJ, Mulliken JB, et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet. 2017;100:546–54.PubMedPubMedCentralCrossRef Couto JA, Huang AY, Konczyk DJ, Goss JA, Fishman SJ, Mulliken JB, et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet. 2017;100:546–54.PubMedPubMedCentralCrossRef
6.
go back to reference Al-Olabi L, Polubothu S, Dowsett K, Andrews KA, Stadnik P, Joseph AP, et al. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Investig. 2018;128:1496–508.PubMedPubMedCentralCrossRef Al-Olabi L, Polubothu S, Dowsett K, Andrews KA, Stadnik P, Joseph AP, et al. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Investig. 2018;128:1496–508.PubMedPubMedCentralCrossRef
7.
go back to reference Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015;97:914–21.PubMedPubMedCentralCrossRef Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015;97:914–21.PubMedPubMedCentralCrossRef
8.
go back to reference Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016;8:332ra42.PubMedPubMedCentralCrossRef Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016;8:332ra42.PubMedPubMedCentralCrossRef
9.
go back to reference Palmieri M, Di Sarno L, Tommasi A, Currò A, Doddato G, Baldassarri M, et al. MET somatic activating mutations are responsible for lymphovenous malformation and can be identified using cell-free DNA next generation sequencing liquid biopsy. J Vasc Surg Venous Lymphat Disord. 2021;9:740–4.PubMedCrossRef Palmieri M, Di Sarno L, Tommasi A, Currò A, Doddato G, Baldassarri M, et al. MET somatic activating mutations are responsible for lymphovenous malformation and can be identified using cell-free DNA next generation sequencing liquid biopsy. J Vasc Surg Venous Lymphat Disord. 2021;9:740–4.PubMedCrossRef
10.
go back to reference Blesinger H, Kaulfuß S, Aung T, Schwoch S, Prantl L, Rößler J, et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. PLoS ONE. 2018;13: e0200343.PubMedPubMedCentralCrossRef Blesinger H, Kaulfuß S, Aung T, Schwoch S, Prantl L, Rößler J, et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. PLoS ONE. 2018;13: e0200343.PubMedPubMedCentralCrossRef
11.
go back to reference Osborn AJ, Dickie P, Neilson DE, Glaser K, Lynch KA, Gupta A, et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet. 2015;24:926–38.PubMedCrossRef Osborn AJ, Dickie P, Neilson DE, Glaser K, Lynch KA, Gupta A, et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet. 2015;24:926–38.PubMedCrossRef
12.
go back to reference Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16:306.PubMedPubMedCentralCrossRef Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16:306.PubMedPubMedCentralCrossRef
13.
go back to reference Le Cras TD, Goines J, Lakes N, Pastura P, Hammill AM, Adams DM, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis. 2020;23:425–42.PubMedPubMedCentralCrossRef Le Cras TD, Goines J, Lakes N, Pastura P, Hammill AM, Adams DM, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis. 2020;23:425–42.PubMedPubMedCentralCrossRef
14.
go back to reference Kane G, Fernandez-Pineda I. Targeted therapies for vascular malformations. Front Med. 2024;11:1446046.CrossRef Kane G, Fernandez-Pineda I. Targeted therapies for vascular malformations. Front Med. 2024;11:1446046.CrossRef
15.
go back to reference Greene AK, Orbach DB. Management of arteriovenous malformations. Clin Plast Surg. 2011;38:95–106.PubMedCrossRef Greene AK, Orbach DB. Management of arteriovenous malformations. Clin Plast Surg. 2011;38:95–106.PubMedCrossRef
16.
go back to reference Liu AS, Mulliken JB, Zurakowski D, Fishman SJ, Greene AK. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125:1185–94.PubMedCrossRef Liu AS, Mulliken JB, Zurakowski D, Fishman SJ, Greene AK. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125:1185–94.PubMedCrossRef
17.
go back to reference Seront E, Hermans C, Boon LM, Vikkula M. Targeted treatments for vascular malformations: current state of the art. J Thromb Haemost. 2024;22:2961–75.PubMedCrossRef Seront E, Hermans C, Boon LM, Vikkula M. Targeted treatments for vascular malformations: current state of the art. J Thromb Haemost. 2024;22:2961–75.PubMedCrossRef
18.
go back to reference Mansur A, Radovanovic I. Vascular malformations: an overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. Front Neurol. 2023;14:1099328.PubMedPubMedCentralCrossRef Mansur A, Radovanovic I. Vascular malformations: an overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. Front Neurol. 2023;14:1099328.PubMedPubMedCentralCrossRef
19.
go back to reference Palmieri M, Currò A, Tommasi A, Di Sarno L, Doddato G, Baldassarri M, et al. Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation. JVS Vasc Sci. 2020;1:176–80.PubMedPubMedCentralCrossRef Palmieri M, Currò A, Tommasi A, Di Sarno L, Doddato G, Baldassarri M, et al. Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation. JVS Vasc Sci. 2020;1:176–80.PubMedPubMedCentralCrossRef
20.
go back to reference Li D, Sheppard SE, March ME, Battig MR, Surrey LF, Srinivasan AS, et al. Genomic profiling informs diagnoses and treatment in vascular anomalies. Nat Med. 2023;29:1530–9.PubMedPubMedCentralCrossRef Li D, Sheppard SE, March ME, Battig MR, Surrey LF, Srinivasan AS, et al. Genomic profiling informs diagnoses and treatment in vascular anomalies. Nat Med. 2023;29:1530–9.PubMedPubMedCentralCrossRef
21.
go back to reference Serio VB, Palmieri M, Loberti L, Granata S, Fallerini C, Vaghi M, et al. Nosological and theranostic approach to vascular malformation through cfDNA NGS liquid biopsy. J Clin Med. 2022;11:3740.PubMedPubMedCentralCrossRef Serio VB, Palmieri M, Loberti L, Granata S, Fallerini C, Vaghi M, et al. Nosological and theranostic approach to vascular malformation through cfDNA NGS liquid biopsy. J Clin Med. 2022;11:3740.PubMedPubMedCentralCrossRef
22.
go back to reference Eyries M, Montani D, Nadaud S, Girerd B, Levy M, Bourdin A, et al. Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. Eur Respir J. 2019;53:1801371.PubMedCrossRef Eyries M, Montani D, Nadaud S, Girerd B, Levy M, Bourdin A, et al. Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. Eur Respir J. 2019;53:1801371.PubMedCrossRef
23.
go back to reference Zenner K, Jensen DM, Cook TT, Dmyterko V, Bly RA, Ganti S, et al. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations. Genet Med. 2021;23:123–30.PubMedCrossRef Zenner K, Jensen DM, Cook TT, Dmyterko V, Bly RA, Ganti S, et al. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations. Genet Med. 2021;23:123–30.PubMedCrossRef
24.
go back to reference Palmieri M, Pinto AM, di Blasio L, Currò A, Monica V, Sarno LD, et al. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel–Trenaunay syndrome. Vascular. 2021;29:85–91.PubMedCrossRef Palmieri M, Pinto AM, di Blasio L, Currò A, Monica V, Sarno LD, et al. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel–Trenaunay syndrome. Vascular. 2021;29:85–91.PubMedCrossRef
25.
go back to reference Serio VB, Palmieri M, Innamorato S, Loberti L, Fallerini C, Ariani F, et al. Case report: PIK3CA somatic mutation leading to Klippel Trenaunay syndrome and multiple tumors. Front Genet. 2023;14:1213283.PubMedPubMedCentralCrossRef Serio VB, Palmieri M, Innamorato S, Loberti L, Fallerini C, Ariani F, et al. Case report: PIK3CA somatic mutation leading to Klippel Trenaunay syndrome and multiple tumors. Front Genet. 2023;14:1213283.PubMedPubMedCentralCrossRef
26.
go back to reference Conde AJ, Keraite I, Leslie NR, Kersaudy-Kerhoas M. Microfluidic acoustic method for high yield extraction of cell-free DNA in low-volume plasma samples. In: Garcia-Cordero JL, Revzin A, editors. Microfluidic systems for cancer diagnosis. New York: Springer, US; 2023. p. 163–80.CrossRef Conde AJ, Keraite I, Leslie NR, Kersaudy-Kerhoas M. Microfluidic acoustic method for high yield extraction of cell-free DNA in low-volume plasma samples. In: Garcia-Cordero JL, Revzin A, editors. Microfluidic systems for cancer diagnosis. New York: Springer, US; 2023. p. 163–80.CrossRef
27.
28.
go back to reference Sater V, Viailly P-J, Lecroq T, Prieur-Gaston É, Bohers É, Viennot M, et al. UMI-VarCal: a new UMI-based variant caller that efficiently improves low-frequency variant detection in paired-end sequencing NGS libraries. Bioinformatics. 2020;36:2718–24.PubMedCrossRef Sater V, Viailly P-J, Lecroq T, Prieur-Gaston É, Bohers É, Viennot M, et al. UMI-VarCal: a new UMI-based variant caller that efficiently improves low-frequency variant detection in paired-end sequencing NGS libraries. Bioinformatics. 2020;36:2718–24.PubMedCrossRef
29.
go back to reference Brouillard P, Schlögel MJ, Homayun Sepehr N, Helaers R, Queisser A, Fastré E, et al. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations. Orphanet J Rare Dis. 2021;16:267.PubMedPubMedCentralCrossRef Brouillard P, Schlögel MJ, Homayun Sepehr N, Helaers R, Queisser A, Fastré E, et al. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations. Orphanet J Rare Dis. 2021;16:267.PubMedPubMedCentralCrossRef
30.
go back to reference Sun Y, Cai R, Wang Z, Wang D, Zhao X, Yue X, et al. Plasma cell-free DNA after embolization: a novel, sensitive method for the molecular diagnosis of venous malformations. J Vasc Anom. 2023;4: e054. Sun Y, Cai R, Wang Z, Wang D, Zhao X, Yue X, et al. Plasma cell-free DNA after embolization: a novel, sensitive method for the molecular diagnosis of venous malformations. J Vasc Anom. 2023;4: e054.
31.
go back to reference Pang M, Zhang G, Shang C, Zhang Y, Chen R, Li Z, et al. Advances in the study of KRAS in brain arteriovenous malformation. Cerebrovasc Dis Basel Switz. 2024;53:767–75. Pang M, Zhang G, Shang C, Zhang Y, Chen R, Li Z, et al. Advances in the study of KRAS in brain arteriovenous malformation. Cerebrovasc Dis Basel Switz. 2024;53:767–75.
32.
go back to reference Nikolaev SI, Vetiska S, Bonilla X, Boudreau E, Jauhiainen S, Rezai Jahromi B, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378:250–61.PubMedPubMedCentralCrossRef Nikolaev SI, Vetiska S, Bonilla X, Boudreau E, Jauhiainen S, Rezai Jahromi B, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378:250–61.PubMedPubMedCentralCrossRef
33.
go back to reference Oka M, Kushamae M, Aoki T, Yamaguchi T, Kitazato K, Abekura Y, et al. KRAS G12D or G12V mutation in human brain arteriovenous malformations. World Neurosurg. 2019;126:e1365–73.PubMedCrossRef Oka M, Kushamae M, Aoki T, Yamaguchi T, Kitazato K, Abekura Y, et al. KRAS G12D or G12V mutation in human brain arteriovenous malformations. World Neurosurg. 2019;126:e1365–73.PubMedCrossRef
34.
go back to reference Hong T, Yan Y, Li J, Radovanovic I, Ma X, Shao YW, et al. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019;142:23–34.PubMedCrossRef Hong T, Yan Y, Li J, Radovanovic I, Ma X, Shao YW, et al. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019;142:23–34.PubMedCrossRef
35.
go back to reference Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17.PubMedPubMedCentralCrossRef Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17.PubMedPubMedCentralCrossRef
36.
go back to reference Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al. Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Front Oncol. 2022;12:1030232.PubMedPubMedCentralCrossRef Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al. Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Front Oncol. 2022;12:1030232.PubMedPubMedCentralCrossRef
37.
go back to reference Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget. 2015;6:36041–52.PubMedPubMedCentralCrossRef Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget. 2015;6:36041–52.PubMedPubMedCentralCrossRef
38.
go back to reference Mansur A, Radovanovic I. Defining the role of oral pathway inhibitors as targeted therapeutics in arteriovenous malformation care. Biomedicines. 2024;12:1289.PubMedPubMedCentralCrossRef Mansur A, Radovanovic I. Defining the role of oral pathway inhibitors as targeted therapeutics in arteriovenous malformation care. Biomedicines. 2024;12:1289.PubMedPubMedCentralCrossRef
39.
go back to reference Fraissenon A, Bayard C, Morin G, Benichi S, Hoguin C, Protic S, et al. Sotorasib for vascular malformations associated with KRAS G12C mutation. N Engl J Med. 2024;391:334–42.PubMedCrossRef Fraissenon A, Bayard C, Morin G, Benichi S, Hoguin C, Protic S, et al. Sotorasib for vascular malformations associated with KRAS G12C mutation. N Engl J Med. 2024;391:334–42.PubMedCrossRef
40.
go back to reference Edwards EA, Phelps AS, Cooke D, Frieden IJ, Zapala MA, Fullerton HJ, et al. Monitoring arteriovenous malformation response to genotype-targeted therapy. Pediatrics. 2020;146: e20193206.PubMedCrossRef Edwards EA, Phelps AS, Cooke D, Frieden IJ, Zapala MA, Fullerton HJ, et al. Monitoring arteriovenous malformation response to genotype-targeted therapy. Pediatrics. 2020;146: e20193206.PubMedCrossRef
41.
go back to reference Cooke DL, Frieden IJ, Shimano KA. Angiographic evidence of response to trametinib therapy for a spinal cord arteriovenous malformation. J Vasc Anom. 2021;2: e018. Cooke DL, Frieden IJ, Shimano KA. Angiographic evidence of response to trametinib therapy for a spinal cord arteriovenous malformation. J Vasc Anom. 2021;2: e018.
42.
go back to reference Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N, et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med. 2023;25: 100969.PubMedCrossRef Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N, et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med. 2023;25: 100969.PubMedCrossRef
43.
go back to reference Singh S, Bradford D, Li X, Mishra-Kalyani PS, Shen Y-L, Wang L, et al. FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin Cancer Res. 2024;30:23–8.PubMedPubMedCentralCrossRef Singh S, Bradford D, Li X, Mishra-Kalyani PS, Shen Y-L, Wang L, et al. FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin Cancer Res. 2024;30:23–8.PubMedPubMedCentralCrossRef
44.
go back to reference Zerbib L, Ladraa S, Fraissenon A, Bayard C, Firpion M, Venot Q, et al. Targeted therapy for capillary-venous malformations. Signal Transduct Target Ther. 2024;9:146.PubMedPubMedCentralCrossRef Zerbib L, Ladraa S, Fraissenon A, Bayard C, Firpion M, Venot Q, et al. Targeted therapy for capillary-venous malformations. Signal Transduct Target Ther. 2024;9:146.PubMedPubMedCentralCrossRef
Metadata
Title
Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital
Authors
Franck Neil El Sissy
Annouk Bisdorff
Alexandre Perrier
Erell Guillerm
Jérôme Denis
Löetitia Favre
Mathilde Aubertin
Mélanie Eyries
Florence Coulet
Publication date
03-02-2025
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-025-00770-0

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more